The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Plant is part of the company's CAD $30 million capital investment in the site
Brings 25 years of global operations and supply chain experience to Piramal
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)